Home › Mantle Cell Lymphoma › NCT06788652

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma in the Post-Marketing Setting

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

• Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA

Exclusion Criteria:

* Participants known to be participating in investigational studies at the time of liso-cel infusion.
* Participants treated with non-conforming CAR T-cell product.

About the study

The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).

What is being tested

• Lisocabtagene maraleucel (biological)

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Participants: 300 · Started: Feb 4, 2025

Contact the study team

• BMS Study Connect Contact Center www.BMSStudyConnect.com · Phone: 855-907-3286

Official record on ClinicalTrials.gov — NCT06788652

Locations in the U.S.

Conditions

• Mantle Cell Lymphoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.